Chengdu Institute of Biological Products: Application for production registration of tetravalent meningococcal combined vaccine has been accepted.

Chia Tai Bio announcement, the company's wholly-owned subsidiary Chia Tai Green Bamboo's ACYW135 meningococcal polysaccharide conjugate vaccine has applied for production registration and obtained the "Acceptance Notice" issued by the National Medical Products Administration. Currently, there is only one quadrivalent meningococcal conjugate vaccine on the market in China. If this vaccine is approved for market sales, it will synergize with the company's existing meningococcal vaccines, solidify the company's meningococcal vaccine portfolio, strengthen market position, and enhance competitiveness. Drug research and development involves high investment, long cycles, and high risks, the acceptance of the project for production registration will not have a significant impact on the company's recent performance.